Pills-related severe adverse events: A case report in Taiwan  by Chen, Ching-Hui et al.
lable at ScienceDirect
Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 588e590Contents lists avaiTaiwanese Journal of Obstetrics & Gynecology
journal homepage: www.t jog-onl ine.comCase ReportPills-related severe adverse events: A case report in Taiwan
Ching-Hui Chen a, b, Hung-Yen Chin a, b, Huang-Hui Chen a, Heng-Yu Chang c, d, *,
Wei-Min Liu a, b, *
a Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan
b Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
c Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
d Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwana r t i c l e i n f o
Article history:
Accepted 17 March 2016
Keywords:
abnormal uterine bleeding
Diane-35
polycystic ovary syndrome
pulmonary embolism
thromboembolism* Corresponding authors. Heng-Yu Chang, Departm
lecular Cell Biology, Graduate Institute of Medical S
Taipei Medical University, Number 250, WuXing Stree
Taiwan. Wei-Min Liu, Department of Obstetrics and
University Hospital and Taipei Medical University, N
XinYi District, Taipei 11031, Taiwan.
E-mail addresses: hychang@tmu.edu.tw (H.-Y. C
(W.-M. Liu).
http://dx.doi.org/10.1016/j.tjog.2016.03.003
1028-4559/Copyright © 2016, Taiwan Association of O
(http://creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Objective: To review and evaluate the potential adverse effects of these oral contraceptives (OCP) to
overweight women.
Case Report: A 19-year-old college student, with a body mass index (BMI) of 35.2 kg/m2, who received 2
months of OCP containing cyproterone and ethinyl estradiol for polycystic ovary syndrome (PCOS)-related
menstrual problems was complicated with a thromboembolism-related life-threatened disease. After
intensive care, including the use of an extracorporeal membrane oxygenation system, thrombolytic
treatment, anticoagulant, and inferior vena ﬁlter, she recovered well without signiﬁcant sequelae.
Conclusion: This case illustrates the risk of using OCPs, especially for those containing cyproterone and
ethinyl estradiol components, as a treatment for menstrual problems in young women with PCOS and a
high BMI.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Abnormal uterine bleeding (AUB) and its subgroup, heavy
menstrual bleeding is a signiﬁcant and common clinical entity
affecting more than 10% of women of reproductive age [1], leading
to a debilitating health outcome, reduced health-related quality of
life, and a considerable economic burden on the health care system
[2]. To clearly demonstrate AUB, there are nine main categories,
arranged according to the acronym PALM-COEIN (polyp, adeno-
myosis, leiomyomas, malignancy, hyperplasia-coagulopathy,
ovulation dysfunction, endometrial disorders, iatrogenic causes,
and not-yet-classiﬁed entities), which help physicians and patients
to deal with their clinical problems [2]. Medical treatment is one of
the most important and popular therapeutic choices in theent of Biochemistry and Mo-
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regardless of what categories were met [3]. Many agents can be
applied, but hormone therapy may be the most popular, not only
for decreasing the amount of menstruation, but also for regulating
menstrual periods. The current options of hormone therapy mainly
contain estrogen or progestins, either independently or in combi-
nation [i.e., combined oral contraceptives (OCPs)] [1]. Previous
studies have shown that in more than 70% of the cases in which
women received this treatment, the bleeding was stopped effec-
tively [4].
Polycystic ovary syndrome (PCOS) is the most common hor-
monal abnormality syndrome of women of childbearing age [5].
Because irregular uterine bleeding caused by anovulation and
hyperandrogenic status is one of the most apparent symptoms of
PCOS [6], as well as many additional beneﬁts of OCPs which have
been reported, including decreased dysmenorrhea, decreased
blood loss, ovarian cancer prophylaxis, and decreased androgens
[7], it is the rationale to use OCPs in the management of these
women with PCOS. However, women with PCOS have a 1.5 times
higher baseline risk of venous thromboembolism (VTE) and a 3.7-
fold greater effect with OCP use compared with non-PCOS
women [8], but this is rarely emphasized. The following might beby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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PCOS was complicated by OCP-related severe VTE.
Case Report
A 19-year-old female, with a body mass index (BMI) of 35.2 kg/
m2, was diagnosed with PCOS at Taipei Medical University Hospital
by clinical symptoms, gynecological ultrasound, and serum exam-
inations in January 2015. She presented typical symptoms of PCOS,
including oligomenorrhea, irregular cycles and persistent vaginal
bleeding off and on, insulin resistance, and typical ultrasound
ﬁnding of PCOS [9] since April 2015. Low dose hormone therapy,
including medroxyprogesterone acetate (5e10 mg), estrogen
(2e4 mg), and ergometrine maleate (0.6 mg) was prescribed at
ﬁrst, but symptoms persisted. In addition, this young woman could
not tolerate the higher doses of hormone therapy. Finally, OCPs
(Diane-35, cyproterone 2 mg, and ethinyl estradiol 0.035 mg, Bayer
Weimar GmbH und Co. KG, Weimar, Germany) were suggested and
prescribed on April 25.
The patient responded well at the ﬁrst course, although she
experienced right lower leg pain and swelling at the second course
of OCPs (June 3). She did not care too much and did not report it to
the doctors. On June 11, she lost consciousness suddenly and was
brought into the hospital where an electrocardiogram showed
pulseless electrical activity. After 1 hour of cardiopulmonary
resuscitation, vital signs were still unstable and she did not recover
consciousness. Therefore, extracorporeal membrane oxygenation
was set up. Chest computed tomography showed multiple ﬁlling
defects within the bilateral pulmonary arteries, favoring the diag-
nosis of pulmonary embolism. The electrocardiogram reported
right heart enlargement. Serum D-dimer was 25.49 ug/mL.
Thrombolytic treatment was given immediately. Extracorporeal
membrane oxygenation was removed on June 15. She stayed in the
intensive care unit and was transferred to a ward on June 19. An
inferior vena cava ﬁlter was placed in order to prevent further life-
threatening episodes on June 21. She was discharged on June 30,
2015 when her general condition was stabilized. She recovers well
without sequelae at the date of this report, although oral antico-
agulant therapy is continuous.
Discussion
Diane-35/Dianette, which contains ethinylestradiol (35 mg) and
cyproterone acetate (2 mg), provides effective birth control, but is
not indicated as an OCP and is approved only as therapy for
androgen-sensitive skin conditions [10]. However, many physicians
may be unaware of concerns about the drug’s safety proﬁle and the
fact that it is not approved for use solely as an OCP [10]. Although a
Danish study showed no difference in risk of VTE between levo-
norgestrel and cyproterone users [11], a UK study (100,000women)
showed a signiﬁcant four-fold increase of VTE [12]. While there
have been reports of VTE with fatal outcomes after the use of
Diane-35 in the Netherlands, France, and Canada, which elevated
attention to drug safety and led to the suspension of the drug in
France [9,13,14], there are no previous reports in Taiwan or in any
other Asian countries.
To report this case, we used the term “cyproterone, ethinyles-
tradiol, and Asia” (from 1956 to March 15, 2016) to search PubMed
for relevant English-language articles (http://www.ncbi.nlm.nih.
gov/pubmed/?term¼cyproterone%2Cþethinylestradiol%2CþAsia)
and found seven published articles for this topic. However, none of
the articles showed the severe side effects similar to those in our
report. This case illustrates the risk of using OCPs containing
cyproterone as a hormonal treatment for AUB in young women,
particularly in women with PCOS and a high BMI. However, is thefatal risk of OCPs really related to cyproterone components?
Vasilakis-Scaramozza and Jick [12] described a total of 128 women
(cases and controls) who had used levonorgestrel-containing OCPs
and 42 women (cases and controls) who had used cyproterone
acetate-containing OCPs, and found that only 7% of the former
group had used the preparation for 6 months or less, whereas 29%
of the latter group had used the OCPs for 6 months or less, sug-
gesting that there is a greater probability of ﬁrst-time use; thus, the
proportion of women using OCPs for the ﬁrst time appears to have
been higher in the cyproterone acetate-containing OCPs group,
which contributed to some or all of the greater risk of VTE in that
group [15]. The patient in the current report was also a ﬁrst-time
user and developed pulmonary embolism within 2 months, the
most risky period to develop the severe thromboembolic events.
Therefore, OCPs prescribed for any ﬁrst-time users should be
carefully evaluated and discussed. The balance of risks and beneﬁts
should always be taken into consideration to minimize the occur-
rence of catastrophic events.
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